IGC Pharma Advances Alzheimer's Pipeline with Preclinical IGC-M3, Phase 2 Cannabinoid Trials

IGC Pharma, Inc. is advancing its Alzheimer's disease portfolio with promising preclinical and clinical developments focused on cannabinoid-based and small molecule therapies. The company's proprietary cannabinoid formulation IGC-AD1 is currently in Phase 2 clinical trials targeting agitation symptoms in Alzheimer's patients, with potential disease-modifying effects under investigation. Additionally, IGC-M3, a novel small molecule in preclinical development, has demonstrated efficacy in laboratory models by addressing multiple Alzheimer's disease mechanisms including beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. IGC-M3 notably prevented over 90% of beta-amyloid fibril formation and showed antioxidant properties surpassing vitamin C, suggesting its potential to modify disease progression. CEO Ram Mukunda highlighted IGC Pharma's unique dual approach combining late-stage cannabinoid therapy with early-stage multifunctional small molecule development, positioning the company as a differentiated player in addressing a major unmet medical need affecting millions globally. The company anticipates key data readouts in 2026 that could provide significant value for patients, caregivers, and shareholders.